Skip to main content

Day: August 11, 2025

Anteris Announces Results for the Second Quarter of 2025

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 Highlights130 patients implanted with the DurAVR® THV since the start of clinical development; 49 patients treated year-to-date; 21 in the quarter World first “double DurAVR®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions Advanced preparatory work for the DurAVR® THV’s global, pivotal clinical trial (the “PARADIGM Trial”) including...

Continue reading

TPI Composites, Inc. Initiates Voluntary Chapter 11 Proceedings to Facilitate Restructuring to Position Company for Long-Term Success

Reaches Agreement with Senior Secured Lenders for Use of Cash Collateral and Up to $82.5 Million in Debtor-in-Possession Financing, Subject to Final Documentation and Court Approval DIP Financing to Facilitate Path to Comprehensive Restructuring and Support Continued Operations Company Will Continue Operations in Normal Course SCOTTSDALE, Ariz., Aug. 11, 2025 (GLOBE NEWSWIRE) — TPI Composites, Inc. (NASDAQ: TPIC) announced today that it, together with its domestic subsidiaries (collectively, “TPI” or the “Company”), has commenced voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) to pursue a comprehensive restructuring of the Company that will allow the Company to emerge as a stronger enterprise. To support the Company during this process, TPI has reached an...

Continue reading

SPX Announces Proposed Public Offering of Common Stock

CHARLOTTE, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX”) announced today that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering. In addition, SPX intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock offered in the public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Securities, J.P. Morgan, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. TD Cowen and Truist Securities are also acting as book-running managers for the proposed offering. The shares are being offered by SPX pursuant...

Continue reading

Arq Reports Second Quarter 2025 Results

Increased revenue 13% YoY and maintained sustained PAC price improvement Delivered 5th consecutive quarter of positive Adjusted EBITDA – up >200% YoY Achieved major milestone with the commissioning of 1st GAC line at Red River Targeting final investment decision (FID) for 2nd GAC line prior to year-end 2025 GREENWOOD VILLAGE, Colo., Aug. 11, 2025 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter ended June 30, 2025. Financial HighlightsGenerated revenue of $28.6 million in Q2 2025, up 13% over the prior year period, driven largely by higher average sales price (“ASP”), and higher volumes soldIncreased ASP...

Continue reading

Apollo Funds Reach Agreement with American Securities to Acquire Trace3, a Leading Technology Solutions Provider Driving Adoption of Next-Generation Technology and AI

Strategic Investment to Accelerate Trace3’s Growth and Expand Solutions Across Security, Hybrid Cloud and AI IRVINE, Calif. and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that funds managed by its affiliates (the “Apollo Funds”) have agreed to acquire Trace3, a leading provider of enterprise and commercial technology solutions, from American Securities. Financial terms were not disclosed. American Securities will retain a significant minority equity interest in the company. Trace3 is a leading digital transformation and IT solutions provider to commercial and enterprise clients, including many of the Fortune 500. Since its founding in 2002, Trace3 has established a national, market-leading position in the technology solutions provider space with significant expertise in artificial intelligence,...

Continue reading

Proficient Auto Logistics Reports Second Quarter 2025 Financial Results

JACKSONVILLE, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) — Proficient Auto Logistics, Inc. (NASDAQ: PAL) (the “Company” or “Proficient”) today reported its financial results for the three months ended June 30, 2025, and comparative summary financial information for the Founding Companies (as defined below) on a combined basis for the three months ended June 30, 2024. Second Quarter Summary (second quarter 2024 information on a combined basis) Total Operating Revenue of $115.5 million, increased 21.4% from Q1 2025 and 8.4% from Q2 2024 Total Operating Income (Loss) of $0.1 million, versus ($2.4) million in Q1 2025 and $7.0 million in Q2 2024 Adjusted Operating Income(1) of $3.8 million, versus $1.2 million in Q1 2025 and $8.7 million in Q2 2024 Adjusted Operating Ratio(1) of 96.7% compared to 98.7% in Q1 2025 and 91.8% in Q2 2024 Total...

Continue reading

CPS Announces Second Quarter 2025 Earnings

Revenues of $109.8 million compared to $95.9 million in the prior year period Pretax income of $7.0 million compared to $6.7 million in the prior year period Record high shareholder’s equity- first time over $300 million New contract purchases of $433.0 million in the quarterLAS VEGAS, NV, Aug. 11, 2025 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.8 million, or $0.20 per diluted share, for its second quarter ended June 30, 2025. This represents an increase compared to net income of $4.7 million, or $0.19 per diluted share, in the second quarter of 2024. Revenues for the second quarter of 2025 were $109.8 million, an increase of $13.9 million, or 14.5%, compared to $95.9 million for the second quarter of 2024. Total operating expenses for the second...

Continue reading

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years  In June 2025, the Company was added to the Russell 3000® and Russell 2000® Indexes following the annual reconstitution Phase 3 RESILIENT results published in peer-reviewed journal, Pain Medicine, including statistically significant reduction in fibromyalgia pain with once‑nightly TNX‑102 SL; generally well tolerated Cash and cash equivalents of $125.3 million reported as of June 30, 2025; current cash runway expected to fund operations into the third quarter of 2026 CHATHAM, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a...

Continue reading

3D Systems Reports Second Quarter 2025 Financial Results

ROCK HILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025.Revenue of $95 million led by double-digit growth in Medical Technology and Aerospace & Defense markets Regenerative Medicine partnership with United Therapeutics targeted on manufacture of human lungs reached a new printing milestone resulting in a $2 million award in the quarter Cost reduction and efficiency programs resulted in over $20 million of savings in operating expenses in Q2 Company’s previously announced cost initiatives are on track to support a return to positive cash flow in 2026 Successful balance sheet restructuring, combining debt retirement, refinancing, and share repurchase, allows for execution of restructuring program while maintaining continuity...

Continue reading

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCC Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)BRISBANE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended June 30, 2025 and provided a corporate update. “We...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.